1stOncology™: Cancer Intelligence Service – Page 6567 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

FY2021 Summary

On May 12, 2022 Kureha Corporation reported that FY2021 Financial ReportI (Press release, Kureha Corporation, MAY 12, 2022, View Source [SID1234614277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

FY2021 Results (April 1, 2021 – March 31, 2022)

2 Highlights
• Delivered ¥6.5bn growth in core operating profit, driven by Advanced Materials (PVDF, PPS) and Specialty Plastics (wrap film, fishing lines)
• PPS capacity increase of 5000tpa (completed by FY20/4Q) contributing in 2Q onward
• Capacity increase for PVDF specialty polymers completed at the Iwaki Factory in 4Q
• Sales growth of PGA frac plugs below targeted; PGA resin production suspended
• Development of new agrochemicals progressing as scheduled
• Recorded a ¥5.3bn impairment loss on the PGA resin manufacturing plant (USA)Factors attributing to changes in

core operating profit AM: Sales expansion of advanced plastics (PVDF, PPS, PGA), carbon products and other plastic products SC: Higher fuel and raw material costs more than offsetting increased pharmaceuticals and organic industrial chemicals volumes, flat agrochemicals sales

SP: Higher home product and fishing line volumes, recovered sales for packaging materials
CO: Fewer construction projects in both private and public sectors
OO: Absence (completion) of prior year’s post-typhoon waste treatment projectsNotes-Other expenses in FY2020 include an ¥1.6bn impairment loss related to the PGA business

-Other expenses in FY2021 include a ¥5.3bn impairment loss related to the PGA business and a ¥0.3bn loss on revision of retirement benefit plan

Advanced plastics: Revenue and profit up: Higher sales volumes of PVDF LiB binder, PPS and PGA (for shale development) partially offset by impact of suspended production for PGA resins
Carbon products: Revenue and profit up: Sales volume growth of carbon fiber used for high-heat furnace insulation and automotive sliding materials
Other: Revenue and profit up: Sales expansion of other plastic products led by Group companies

Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2022(PDF?169KB)

On May 12, 2022 Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) reported certain differences between its financial forecast on November 10, 2021, for the fiscal year ended March 31, 2022 (April 1, 2021, to March 31, 2022) (Press release, Sysmex, MAY 12, 2022, View Source [SID1234614269]). Furthermore, at a meeting of the Managing Board on May 12, 2022, Sysmex resolved to award dividends from surplus as described below, with a record date of March 31, 2022. We intend to propose this payment of dividends from surplus at the General Meeting of Shareholders scheduled for June 24, 2022.

1. Change from Financial Forecasts
(1) Consolidated Financial Results for Fiscal Year from April 1, 2021, to March 31, 2022
(2) Reason Consolidated net sales were higher than previously expected, owing to favorable sales in the EMEA region and lower yen exchange rates than we had assumed earlier. On the profit front, operating profit, profit before tax and profit attributable to owners of the parent outpaced our previous expectations due to higher-than-expected consolidated net sales and a decline in selling, general and administrative expenses, owing to sales activities being constrained due to COVID-19. A change in the accounting treatment of cloud computing contracts during the fiscal year under review has been applied retroactively to the previous fiscal year’s figures, which are provided for reference. For details, please see the "Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2022," disclosed today (May 12, 2022).

2. Dividend from Surplus
(1) Dividend
(2) Reason In terms of returns to shareholders, we intend to provide a stable dividend on a continuous basis and aim for a consolidated payout ratio of 30% under our basic policy of sharing the successes of our operations in line with business performance.

In accordance with this policy, we have set the ordinary year-end dividend for the fiscal year ended March 31, 2022, at ¥39 per share. Accordingly, annual total dividends will be ¥76 and the consolidated payout ratio will be 36.0%.

Isofol Medical AB (publ) publishes interim report, January–March 2022

On May 12, 2022 Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), reported that the company’s interim report for January–March 2022 is now available on the company’s website, www.isofolmedical.com (Press release, Isofol Medical, MAY 12, 2022, View Source [SID1234614268]).

First quarter, January–March 2022
● Net revenue amounted to TSEK 4,006 (5,215) and other revenue to TSEK 1 (0)
● The result for the period amounted to TSEK -47,874 (-42,662)
● Earnings per share amounted to SEK -0.30 (-0.51)
● Cash and cash equivalents on March 31 amounted to TSEK 332,035 (77,524)

Significant events during the first quarter 2022
● Jenny Sundqvist assumed her role as Chief Commercial Officer on January 1, 2022.

Significant events after the event of the period
● Isofol’s Nomination Committee proposes the election of Jan Törnell as new Chairman of the Board at the Annual General Meeting on May 19, 2022.
● On April 22, Isofol announced that the process of analyzing study data from the AGENT study has begun.

CEO´s comment:
"During the first quarter, Isofol performed many crucial and important activities to lay the foundation for the presentation of the forthcoming study results in the AGENT study. Having now passed the cut-off point that enables the start of the data analysis process, we see several milestones ahead, presentation of top-line data and later also final data", says CEO Ulf Jungnelius.

Audiocast, May 12, at 11:00 a.m. CEST
In conjunction with the publication of the interim report for the first quarter of 2022, Isofol invites investors, analysts, and media to an audiocast on May 12, 2022 at 11:00 a.m. CEST. The presentation will be held by Isofol´s CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment the report, followed by a Q&A-session. The presentation will be held in English.

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST, on May 12, 2022.

About arfolitixorin
Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global pivotal Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers

On May 12, 2022 Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, reported the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers (Press release, Crown Bioscience, MAY 12, 2022, View Source [SID1234614267]).

The new entity named "Crown Bioscience & MBL", is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.

Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.

The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.

Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: "Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector."

Hiroki Itou, President of Crown Bioscience & MBL commented: "Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan."

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

On May 12, 2022 Curium reported confirmed no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium 177Lu-PSMA-I&T treatment compared to the standard of care hormone therapy in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) (Press release, Curium, MAY 12, 2022, View Source [SID1234614266]). Curium continues to provide clinical trial supply, and enroll patients in the ECLIPSE clinical trial with no disruptions.

"Earlier this month we announced significant progress in our ECLIPSE clinical trial. We are enrolling eligible patients into our study of 177Lu-PSMA-I&T without disruption, which is a testament to our surety of supply. Reliability is a core competency for Curium and is fundamental to fulfilling our purpose of redefining the experience of cancer through our trusted legacy in nuclear medicine," said Renaud Dehareng, Curium’s Group CEO.

"We are thrilled to be able to reliably support our patients, investigators and clinical trial sites," said Sakir Mutevelic, MD, Curium’s Chief Medical Officer. "We remain committed to patients with metastatic castration-resistant prostate cancer."

For more information about the ECLIPSE Trial, visit Curium’s Clinical Trial website View Source or contact Curium’s Clinical Trial team directly at [email protected] with questions or to locate a clinical trial site near you.